Browse the evidence

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.

If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.

Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.

While postmarketing reports of neoplasms are higher for GLP-1 RAs, they are still rare. The benefits of weight loss and mortality reduction likely outweigh this small risk for most patients.

Semaglutide is associated with a higher incidence of symptomatic gastrointestinal adverse events compared to dulaglutide in the context of emergency exposures.

If you experience severe nausea or vomiting on semaglutide, talk to your doctor. They might switch you to a different GLP-1 medication, like dulaglutide, which may have fewer gastrointestinal side effects for you.

Combining calcium beta-hydroxy-beta-methylbutyrate (CaHMB) supplementation with resistance training amplifies body fat reduction compared to resistance training alone, mediated by increased FNDC-5 gene expression and irisin concentration in white adipose tissue.

If you are doing resistance training, adding CaHMB (320 mg/kg/day) may help you lose more body fat than training alone by boosting irisin levels in fat tissue. This is based on rat studies, so human dosing may vary, but the synergy between the supplement and exercise is clear.

Obesity involves molecular mechanisms, including metabolic memory and epigenetic modifications, that actively hinder weight loss and promote weight regain.

If you are struggling to lose weight despite diet and exercise, recognize that your body has biological defenses (like metabolic memory and hormonal shifts) that actively work to restore previous weight. This is not a failure of willpower but a known physiological response. Addressing these barriers may require a multidisciplinary approach, potentially including medical interventions, rather than just stricter dieting.

Epigenetic changes, such as DNA methylation and histone modifications, can persist after weight loss and contribute to weight regain.

Weight loss can trigger long-lasting epigenetic changes that make your body more prone to regaining weight. This means maintaining weight loss might require ongoing effort and potentially medical support, as your body's 'default setting' may have shifted.

Adipose tissue dysfunction, characterized by chronic low-grade inflammation and insulin resistance, creates a self-perpetuating cycle that promotes obesity.

Excess fat, especially around the abdomen, is not just inert storage but an active organ that releases inflammatory signals. These signals can cause insulin resistance and further fat storage, creating a cycle that is hard to break without addressing the underlying inflammation.

GLP-1 receptor agonists may interact with oral systemic cancer therapies by delaying gastric emptying, potentially altering absorption kinetics (time to peak concentration) without necessarily changing total drug exposure.

If you take oral cancer pills along with GLP-1 drugs (like Ozempic), tell your doctor. The GLP-1 drug might slow down how fast your cancer pills are absorbed. This doesn't always mean the treatment won't work, but your doctor needs to know to monitor you closely.

GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.

In Brazil, access to GLP-1 drugs like semaglutide is currently determined by your state's economic wealth rather than your obesity rates. Public health policy has excluded these drugs from free coverage, creating a market where only those with higher income can afford them, regardless of medical need.

Semaglutide is the predominant GLP-1 RA in Brazil, driving the majority of sales growth and adverse event reports, with significant off-label use for weight loss.

Semaglutide is the most widely used GLP-1 drug in Brazil. A significant portion of its use is off-label for weight loss, which generates specific adverse event reports and requires careful monitoring.

GLP-1 receptor agonist therapy (semaglutide/tirzepatide) is increasingly driving referrals for post-weight-loss body contouring, with referral volumes growing faster than those from lifestyle modification or bariatric surgery.

If you are using GLP-1 medications like Ozempic or Mounjaro, be aware that rapid weight loss often leads to excess skin. You may need to consult a plastic surgeon for body contouring procedures. This is a common and expected outcome of significant weight loss via these medications.

In type 2 diabetes, worsening chronic glycaemic control (higher HbA1c) shifts endogenous GIP action from insulinotropic to glucagonotropic, strengthening the correlation between GIP and glucagon secretion while weakening its correlation with insulin.

For people with Type 2 Diabetes, the effectiveness of the body's natural GIP response depends heavily on how well blood sugar is controlled. If HbA1c is high, GIP may contribute to higher glucagon (raising blood sugar) rather than helping insulin. This suggests that managing baseline blood sugar is crucial for optimizing natural hormonal responses.

Expanding first-level genetic screening for obesity to include POMC and MC3R genes is necessary to maximize diagnostic yield and identify patients with intermediate susceptibility phenotypes who are missed by standard panels.

If you have obesity and standard genetic tests came back negative, ask your doctor about expanded testing for POMC and MC3R genes. This can reveal if you have a specific biological susceptibility that might affect how your body handles energy, potentially guiding more personalized treatment strategies.

GLP-1 and dual GIP/GLP-1 receptor agonists exert neuropsychiatric effects by modulating central neurotransmitter systems (dopamine, serotonin, GABA, glutamate) and promoting neuroplasticity, potentially treating addiction, depression, and cognitive decline.

GLP-1 and dual agonists (like semaglutide and tirzepatide) do more than just suppress appetite; they interact with brain receptors that regulate mood, reward, and memory. While they are primarily prescribed for diabetes and weight loss, research suggests they may also help with conditions like addiction, depression, and cognitive decline by balancing neurotransmitters like dopamine and serotonin. However, patients should be aware that while serious psychiatric side effects are rare and not consistently linked to the drugs, isolated reports of mood changes exist, so monitoring mental health is recommended.

GLP-1RAs are associated with rare but serious adverse events including acute pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, though causal relationships for some (like thyroid cancer) are not confirmed in humans.

Be aware of rare but serious side effects like pancreatitis, gallbladder disease, and worsening of diabetic retinopathy (especially if you have pre-existing eye disease). While the risk of thyroid cancer is a concern in animal studies, no human cases have been confirmed. Report any severe abdominal pain or vision changes to your doctor.

Topical cosmetic peptides (e.g., GHK-Cu, Matrixyl, Argirelin) reduce wrinkles and improve skin firmness with excellent safety profiles, though effects are modest and require consistent long-term use.

Topical peptides like GHK-Cu, Matrixyl, and Argirelin can help reduce wrinkles and improve skin firmness when applied consistently over 8-12 weeks. They are generally safe and well-tolerated, but the effects are modest compared to injectable treatments. Regular use is necessary to maintain benefits.

High-dose tirzepatide (10–15 mg/week) is associated with a statistically significant increase in the risk of acute kidney injury (AKI) compared to control treatments.

If you are prescribed high-dose tirzepatide (10-15 mg/week), be aware of a small but statistically significant increased risk of acute kidney injury. Stay well-hydrated, especially if you experience gastrointestinal side effects like nausea or diarrhea, as volume depletion can trigger AKI. Monitor your kidney function as recommended by your doctor, and report any sudden changes in urination or swelling immediately.

Restoring mitochondrial function and physiological superoxide production via AMPK activation (through exercise, caloric restriction, or medications) improves diabetic organ dysfunction, contrary to the theory that excess superoxide drives complications.

For individuals with diabetes, focusing on lifestyle interventions that naturally stimulate mitochondrial health—specifically exercise and caloric restriction—may be more effective than antioxidant supplementation. These actions activate AMPK, restoring mitochondrial function and potentially improving kidney, heart, and nerve health. The goal is not to eliminate all oxidative stress, but to restore healthy mitochondrial signaling.

Weight loss and insulin resistance increase the release of persistent organic pollutants (POPs) from adipose tissue into circulation, potentially causing adverse metabolic and cardiovascular effects that counteract the benefits of fat loss.

If you are overweight and have a high body burden of environmental chemicals (common in modern diets), rapid or intensive weight loss may temporarily increase your exposure to these toxins, potentially offsetting early health gains. To mitigate this, focus on strategies that help eliminate POPs, such as increasing dietary fiber (especially lignins from whole grains), ensuring good bile flow (e.g., through time-restricted feeding or exercise), and reducing intake of high-POP foods like fatty animal products. Avoid yo-yo dieting, as weight cycling repeatedly mobilizes these toxins.

Adipose tissue serves as a protective reservoir for persistent organic pollutants (POPs), reducing their burden on critical organs like the brain and liver, provided insulin resistance and uncontrolled lipolysis are absent.

In modern society, where environmental toxins are ubiquitous, having some adipose tissue may offer a protective buffer against these chemicals reaching vital organs. However, this protection is lost if you have insulin resistance or undergo rapid weight loss, which releases these toxins. Therefore, maintaining metabolic health (insulin sensitivity) is crucial to keeping this protective sequestration effective.

Pinitol-enriched beverage intake increases serum levels of Complement C4A and IGF1BP-ALS in individuals with Impaired Glucose Tolerance (IGT), which correlates with increased GLUT2 expression in the jejunum.

This node describes the biological mechanism rather than a direct user action. It suggests that the glucose-lowering effect of pinitol is mediated by specific protein changes (C4A, IGF1BP-ALS) and gut glucose transporter expression (GLUT2), particularly in those with pre-diabetic conditions.

Chronic low-grade inflammation and oxidative stress in MASLD drive atrial structural and electrical remodeling, creating an arrhythmogenic substrate for AF.

Treating MASLD involves more than just liver health; it requires addressing systemic inflammation and oxidative stress to protect the heart from structural remodeling that leads to AF.

Central administration of leptin or FGF1 can reverse basal hyperglycemia in diabetic animal models through insulin-independent mechanisms, without improving glucose tolerance.

This finding in animals suggests that targeting the brain with specific hormones (like leptin or FGF1) can lower blood sugar without needing insulin. This supports the development of brain-targeted therapies for diabetes that work independently of pancreatic insulin secretion.

Higher expression of Cardiotrophin-1 (CT-1) in subcutaneous femoral adipose tissue (scFEM) is associated with lower visceral adiposity, lower intrahepatic lipid, and greater insulin sensitivity in women with obesity.

For women with obesity, higher levels of the adipokine CT-1 in the femoral (thigh/buttock) fat depot are linked to better metabolic health, including lower liver fat and better insulin sensitivity. This suggests that lower-body fat distribution may be metabolically protective compared to abdominal fat, potentially mediated by CT-1 secretion.